相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium
Le Jiang et al.
HEART RHYTHM (2019)
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
Jennifer R. Brown et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management
Bronwyn C. Thorp et al.
LEUKEMIA & LYMPHOMA (2018)
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
Susan O'Brien et al.
BLOOD (2018)
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib
Jari M. Tuomi et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Lisa S. Chen et al.
BLOOD (2018)
Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab
R. Quintavalla et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2018)
appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies)
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2017)
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
L. Kazianka et al.
LEUKEMIA (2017)
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Heidi D. Finnes et al.
LEUKEMIA & LYMPHOMA (2017)
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)
Tait D. Shanafelt et al.
LEUKEMIA & LYMPHOMA (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
NCCN Guidelines® Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
William G. Wierda et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
J. J. Shatzel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib
Khai Li Chai et al.
LEUKEMIA & LYMPHOMA (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
Jeffrey A. Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Darryl P. Leong et al.
BLOOD (2016)
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Stephen P. Mulligan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
L. de Zwart et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis
Raed A. Joundi et al.
STROKE (2016)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Myocardial 3-Dimensional Printing for Septal Myectomy Guidance in a Patient With Obstructive Hypertrophic Cardiomyopathy
Dong Hyun Yang et al.
CIRCULATION (2015)
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Andrew H. Lipsky et al.
HAEMATOLOGICA (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants
Jan de Jong et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension
Giuseppe Mancia et al.
BLOOD PRESSURE (2014)
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
A. John Camm et al.
EUROPEAN HEART JOURNAL (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Aspirin dose for the prevention of cardiovascular disease - A systematic review
Charles L. Campbell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes - Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study
RJG Peters et al.
CIRCULATION (2003)
分享论文
